Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Sarepta Therapeutics, Inc. reported revenue of $2.20B, up 15.6% year over year. Operating margin was -31.8% and net margin -32.5%, on a free-cash-flow margin of -14.0% with capital expenditure at 4.6% of revenue. Every figure is computed directly from SRPT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2.20B | -31.8% | -32.5% |
| FY2024 | $1.90B | 11.5% | 12.4% |
| FY2023 | $1.24B | -21.5% | -43.1% |
| FY2022 | $933M | -57.5% | -75.4% |
| FY2021 | $702M | -65.5% | -59.7% |
How does SRPT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.